Contribute Try STAT+ Today

A lot more Covid-19 patients in the U.S. are being treated with Gilead Sciences’ remdesivir because of the accelerating case counts. But even with sales of the medicine surging, investors are not impressed.

Shares of Gilead, which markets remdesivir as Veklury, closed down Monday by just under 1% to $62.51 despite the biotech announcing updated and sharply higher product sales guidance for 2020, which included anticipated Veklury sales of $2.8 billion.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I don’t get it. Why won’t GILD considers cutting the Veklury priced by day 1/3. If the treatment volume doubled subsequently, then it Ed ould still be, big win for 203#, right?

    What happened to the abandoned yoralties to the Indian and Bangladesh companies? Heck even at only say $20 per dose, it adds, up right?

    Woykd the company disclose Veklury revenue figures from Eropean, Japanese and other Asian countries at the next quarterly analysts call? We all know the recess nt repeat outbreaks in Japan is quite significant, right?

    Does GILD even have a global Veklury strategy similar to what they had with HIV and HCV drugs? Zi highly doubt that. O’Day at the helm does not possess requisite leadership nor expertise. His unilateral focus on oncogy has brought nothing positive for this compsny since he took over IMO. With him steering the shop. All we see is repeated foam abyss of 52 week SP lows. It is sad to see even a seasoned and well-respected analyst such as Adam won’t come down hard on Dan, yet. Time is ticking though.

Comments are closed.